News About: Pharm. Industry
Genexine succeeds in transferring ‘Interleukin 7’ technology worth of total USD 560 million
Genexine succeeded in transferring technology worth of total USD 560 million.
Genexine publicly announced the company signed a technology transfer agreement of ‘Interleukin 7(long-acting IL-7 cytokine designated as ...
Daewoong Pharmaceutical’s first shipment from new Nabota Factory
Daewoong Pharmaceutical(CEO Jong-Wook Lee) has first shipped the item which was first manufactured at ‘Nabota’ Factory 2 on the 20th. Nabota Factory 2 has acquired KGMP approval from the Ministry of Food and Drug Safe...
What are reasons Korean pharmas rarely develop novel drugs on their own?
Korean pharmaceutical companies have rarely produced self-developed novel drugs.
According to the Ministry of Food and Drug Safety(MFDS), since ‘Sunpla Inj,’ a SK Chemicals’ anticancer drug, acquired approval as the...
Huons introduce asthma treatment with new combination for first time in Korea
Huons(CEO Gi-Ahn Eum), a subsidiary of Huons Global, signed an exclusive distribution license agreement of ‘Zephirus,’ a inhaled capsule for the treatment of asthma, in Korea with Belgian Laboratoires SMB S.A.(SMB) at...
2 of 3 medicines approved as orphan drug was ‘anticancer drug’ this year
This year, 2 of 3 products approved as orphan drug were reportedly an anticancer drug.
Also, 2 products were generated by Korean pharmaceutical companies as an orphan drug by acquiring the preferential sale product ...
Mitsubishi Tanabe notifies Kolon Life Science cancellation of ‘Invossa’ technology agreement
Kolon Life Science(CEO Woo-Seok Lee) announced on the 19th Mitsubishi Tanabe Pharma(MTPC) notified the company cancellation of Invossa technology export and to return the upfront payment of JPY 2.5 billion(approx. KRW...
[Focus] Which will acquire CJ HealthCare for KRW 1 trillion, pharma or private equity fund?
There is now a high chance for CJ HealthCare to be purchased in some way as Kolmar Korea and Korean and foreign private equity funds have decided to join in the preliminary bidding for the company on the 18th.
Despit...
Samsung Bioepis submits biologic application of Herceptin biosimilar in U.S.
Samsung Bioepis(CEO/President Han-Seung Ko) is getting ready to target the U.S. market followed by the European one with ‘SB3(generic name: trastuzumab, European name: ontruzant),’ a biosimilar for the treatment of br...
Daewoong & Samsung Bioepis’ exclusive sales agreement of Samfenet in Korea
Daewoong Pharmaceutical will jump into the ‘anticancer drug field.’
Daewoong Pharmaceutical announced the company signed an exclusive sales agreement of ‘Samfenet,’ an anticancer biosimilar, in Korea with Samsung Bio...
Korean pharmas’ intensified reliability only on developing generic medicines
When it comes to the generic drug development, Korean pharmaceutical companies were analyzed to focus only on medicines with expired patents. This year, there were 625 medicines recognized by bioequivalent test, which...
